123 related articles for article (PubMed ID: 8348501)
1. Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study.
Zhu GG; Stenbäck F; Risteli L; Risteli J; Kauppila A
Cancer; 1993 Sep; 72(5):1679-84. PubMed ID: 8348501
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms.
Zhu GG; Risteli L; Mäkinen M; Risteli J; Kauppila A; Stenbäck F
Cancer; 1995 Feb; 75(4):1010-7. PubMed ID: 7842402
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Kauppila A
Ann Med; 1990 Apr; 22(2):115-21. PubMed ID: 2361007
[TBL] [Abstract][Full Text] [Related]
4. Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum.
Puistola U; Risteli L; Risteli J; Kauppila A
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1276-81. PubMed ID: 2220941
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.
Santala M; Risteli J; Risteli L; Puistola U; Kacinski BM; Stanley ER; Kauppila A
Br J Cancer; 1998 Jun; 77(11):1825-31. PubMed ID: 9667653
[TBL] [Abstract][Full Text] [Related]
6. Aminoterminal propeptide of type III procollagen in ovarian cancer. A review.
Risteli L; Risteli J; Puistola U; Tomás C; Zhu GG; Kauppila A
Acta Obstet Gynecol Scand Suppl; 1992; 155():99-103. PubMed ID: 1502898
[TBL] [Abstract][Full Text] [Related]
7. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum.
Abildgaard N; Bendix-Hansen K; Kristensen JE; Vejlgaard T; Risteli L; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Dec; 99(3):641-8. PubMed ID: 9401078
[TBL] [Abstract][Full Text] [Related]
9. Plasma and tissue levels of collagen types I and III markers in patients with abdominal aortic aneurysms.
Treska V; Topolcan O
Int Angiol; 2000 Mar; 19(1):64-8. PubMed ID: 10853688
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Vuori J; Kauppila A
Cancer; 1990 Dec; 66(11):2399-406. PubMed ID: 2245396
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma.
Santala M; Risteli L; Puistola U; Risteli J; Kauppila A
Ann Med; 1995 Feb; 27(1):57-61. PubMed ID: 7742000
[TBL] [Abstract][Full Text] [Related]
12. Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings.
Haukipuro K; Risteli L; Kairaluoma MI; Risteli J
Surgery; 1990 Apr; 107(4):381-8. PubMed ID: 2321135
[TBL] [Abstract][Full Text] [Related]
13. Effect of gynecological operations on the serum concentration of the aminoterminal propeptide of type III procollagen.
Tomás C; Puistola U; Risteli L; Risteli J; Kauppila A
Acta Obstet Gynecol Scand; 1993 Jul; 72(5):391-5. PubMed ID: 8392273
[TBL] [Abstract][Full Text] [Related]
14. The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology.
Jensen LT
Dan Med Bull; 1997 Feb; 44(1):70-8. PubMed ID: 9062765
[TBL] [Abstract][Full Text] [Related]
15. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
[TBL] [Abstract][Full Text] [Related]
16. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer.
Kauppila A; Puistola U; Risteli J; Risteli L
Cancer Res; 1989 Apr; 49(7):1885-9. PubMed ID: 2924328
[TBL] [Abstract][Full Text] [Related]
17. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.
De Nictolis M; Garbisa S; Lucarini G; Goteri G; Masiero L; Ciavattini A; Garzetti GG; Stetler-Stevenson WG; Fabris G; Biagini G; Prat J
Int J Gynecol Pathol; 1996 Apr; 15(2):102-9. PubMed ID: 8786198
[TBL] [Abstract][Full Text] [Related]
18. Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas.
Wiklund TA; Blomqvist CP; Risteli L; Risteli J; Elomaa I
J Cancer Res Clin Oncol; 1993; 119(3):160-4. PubMed ID: 8418089
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease.
Bolarin DM; Swerdlow P; Wallace AM; Littsey L
Haematologia (Budap); 1998; 29(1):51-8. PubMed ID: 9704258
[TBL] [Abstract][Full Text] [Related]
20. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.
Zhu GG; Risteli J; Puistola U; Kauppila A; Risteli L
Cancer Res; 1993 Oct; 53(20):5028-32. PubMed ID: 8402695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
